CTOs on the Move

Novocure

www.novocure.com

 
We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Funding

Novocure raised $150M on 11/05/2020

Similar Companies

Sanofi

3129 Sanofi SA is a French multinational healthcare company headquartered in Paris, France.

egb Advisors

egb Advisors is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RS BioTherapeutics

BrainsWay

BrainsWay is an Israeli company with international operations that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation as a noninvasive treatment for depression.

Enanta

Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).